{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:57:00Z","timestamp":1791921420225,"version":"4.3.4"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370444"],"award-info":[{"award-number":["82370444"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12411530127"],"award-info":[{"award-number":["12411530127"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["2208085J08"],"award-info":[{"award-number":["2208085J08"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.phrs.2025.107812","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T10:48:15Z","timestamp":1748774895000},"page":"107812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["HIV infection, antiretroviral therapy and vascular dysfunction: Effects, mechanisms and treatments"],"prefix":"10.1016","volume":"217","author":[{"given":"Shulin","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3726-9153","authenticated-orcid":false,"given":"Hans","family":"Strijdom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5488-5217","authenticated-orcid":false,"given":"Suowen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jacbts.2021.10.017","article-title":"HIV, combination antiretroviral therapy, and vascular diseases in men and women[J]","volume":"7","author":"KOVACS","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.phrs.2025.107812_bib2","unstructured":"Global, regional, and national burden of HIV\/AIDS, 1990\u20132021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021[J]. Lancet HIV, 2024, 11(12): e807-e822."},{"issue":"11","key":"10.1016\/j.phrs.2025.107812_bib3","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis[J]","volume":"138","author":"SHAH","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib4","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1161\/CIRCULATIONAHA.107.189625","article-title":"Effects of HIV infection and antiretroviral therapy on the heart and vasculature[J]","volume":"118","author":"Dub\u00e9","year":"2008","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5830\/CVJA-2011-068","article-title":"Endothelial dysfunction: the early predictor of atherosclerosis[J]","volume":"23","author":"MUDAU","year":"2012","journal-title":"Cardiovasc J. Afr."},{"issue":"8","key":"10.1016\/j.phrs.2025.107812_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/cells13080672","article-title":"HIV infection, antiretroviral drugs, and the vascular endothelium[J]","volume":"13","author":"KANMOGNE","year":"2024","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.phrs.2025.107812_bib7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/pharmrev.120.000096","article-title":"Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies[J]","volume":"73","author":"XU","year":"2021","journal-title":"Pharm. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib8","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bbrc.2005.05.198","article-title":"Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins[J]","volume":"333","author":"KANMOGNE","year":"2005","journal-title":"Biochem Biophys. Res Commun."},{"issue":"6","key":"10.1016\/j.phrs.2025.107812_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14923","article-title":"Assessment of coronary artery disease with computed tomography angiography and inflammatory and immune activation biomarkers among adults with hiv eligible for primary cardiovascular prevention[J]","volume":"4","author":"HOFFMANN","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.phrs.2025.107812_bib10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","article-title":"Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection[J]","volume":"24","author":"COLBY","year":"2018","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.phrs.2025.107812_bib11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/cid\/ciab541","article-title":"Time to viral rebound after interruption of modern antiretroviral therapies[J]","volume":"74","author":"LI","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib12","first-page":"152","article-title":"Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression[J]","volume":"39","author":"Fu","year":"2005","journal-title":"J. Acquir Immune Defic. Syndr."},{"issue":"5","key":"10.1016\/j.phrs.2025.107812_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAI.0b013e3180322542","article-title":"Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction[J]","volume":"44","author":"WANG","year":"2007","journal-title":"J. Acquir Immune Defic. Syndr."},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/toxsci\/kfq213","article-title":"Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia[J]","volume":"117","author":"JIANG","year":"2010","journal-title":"Toxicol. Sci."},{"issue":"10","key":"10.1016\/j.phrs.2025.107812_bib15","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.106.652859","article-title":"Endothelial function and dysfunction: testing and clinical relevance[J]","volume":"115","author":"DEANFIELD","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis[J]","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res"},{"key":"10.1016\/j.phrs.2025.107812_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000747","article-title":"Atherosclerosis and HIV: exploring cardiovascular risks and management[J]","author":"SEPLOWE","year":"2024","journal-title":"Cardiol. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib18","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","article-title":"Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the american heart association[J]","volume":"140","author":"FEINSTEIN","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/ATVBAHA.122.318232","article-title":"Cardiovascular disease and thrombosis in HIV infection[J]","volume":"43","author":"PERKINS","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/jac\/dkae049","article-title":"Changes in atherosclerotic cardiovascular disease risk over time among people living with HIV[J]","volume":"79","author":"CHEN","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2025.107812_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12865-015-0106-z","article-title":"Increased inflammation but similar physical composition and function in older-aged, HIV-1 infected subjects[J]","volume":"16","author":"WALLET","year":"2015","journal-title":"BMC Immunol."},{"issue":"23","key":"10.1016\/j.phrs.2025.107812_bib22","article-title":"Lipoprotein(a) is elevated and inversely related to coronary endothelial function in people with HIV[J]","volume":"13","author":"KIKUCHI","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2025.107812_bib23","first-page":"47","article-title":"Endothelial dysfunction and cardiovascular diseases in people living with HIV on specific highly active antiretroviral therapy regimen: a systematic review of clinical studies[J]","volume":"55","author":"MOKOENA","year":"2024","journal-title":"Atheroscler"},{"issue":"3","key":"10.1016\/j.phrs.2025.107812_bib24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/jcm10030392","article-title":"Relationship between endothelial function, antiretroviral treatment and cardiovascular risk factors in HIV patients of African Descent in South Africa: a cross-sectional study[J]","volume":"10","author":"NKEH-CHUNGAG","year":"2021","journal-title":"J. Clin. Med"},{"issue":"6","key":"10.1016\/j.phrs.2025.107812_bib25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/09564624251323681","article-title":"Angiopoietin-2 and endothelial damage associated with viral load in untreated people living with HIV[J]","volume":"36","author":"T\u00d4RRES","year":"2025","journal-title":"Int J. STD AIDS"},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/aid.2021.0052","article-title":"Biomarkers of endothelial activation in Black South African HIV-positive subjects are associated with both high viral load and low CD4 counts[J]","volume":"38","author":"MEZOH","year":"2022","journal-title":"AIDS Res Hum. Retrovir."},{"issue":"9","key":"10.1016\/j.phrs.2025.107812_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101206","article-title":"Association of cardiac troponin T with coronary atherosclerosis in asymptomatic primary prevention people with HIV[J]","volume":"3","author":"DEFILIPPI","year":"2024","journal-title":"JACC Adv."},{"key":"10.1016\/j.phrs.2025.107812_bib28","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.14.04078","article-title":"Higher cardiovascular disease risks in people living with HIV: a systematic review and meta-analysis[J]","volume":"14","author":"ZHU","year":"2024","journal-title":"J. Glob. Health"},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.amjcard.2015.10.030","article-title":"Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013[J]","volume":"117","author":"FEINSTEIN","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2025.107812_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000004165","article-title":"Associations between HIV serostatus and coronary artery plaque volume progression[J]","author":"WHELTON","year":"2025","journal-title":"Aids"},{"issue":"7","key":"10.1016\/j.phrs.2025.107812_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013466","article-title":"Cardiovascular disease burden in rural Africa: does HIV and antiretroviral treatment play a role?: baseline analysis of the ndlovu cohort study[J]","volume":"9","author":"VOS","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.phrs.2025.107812_bib32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosis.2015.03.015","article-title":"Endothelial activation and cardiometabolic profiles of treated and never-treated HIV infected Africans[J]","volume":"240","author":"FOURIE","year":"2015","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.phrs.2025.107812_bib33","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1161\/CIRCRESAHA.124.323891","article-title":"Inflammation in HIV and its impact on atherosclerotic cardiovascular disease[J]","volume":"134","author":"OBARE","year":"2024","journal-title":"Circ. Res"},{"issue":"22","key":"10.1016\/j.phrs.2025.107812_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029541","article-title":"Coronary microcirculatory dysfunction in people with HIV and its association with antiretroviral therapy[J]","volume":"12","author":"HUCK","year":"2023","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/QAD.0b013e328333ea9e","article-title":"Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men[J]","volume":"24","author":"LO","year":"2010","journal-title":"Aids"},{"key":"10.1016\/j.phrs.2025.107812_bib36","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000004184","article-title":"Arterial stiffness in people with HIV: a cross-sectional, comparative study with echocardiographic outcomes in Tanzania[J]","author":"REIS","year":"2025","journal-title":"Aids"},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101572","article-title":"Posttraumatic stress disorder is associated with endothelial dysfunction in women with HIV[J]","volume":"4","author":"VATSA","year":"2025","journal-title":"JACC Adv."},{"issue":"1","key":"10.1016\/j.phrs.2025.107812_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13024-021-00500-0","article-title":"CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice[J]","volume":"16","author":"BHARGAVAN","year":"2021","journal-title":"Mol. Neurodegener."},{"issue":"20","key":"10.1016\/j.phrs.2025.107812_bib39","doi-asserted-by":"crossref","first-page":"10977","DOI":"10.3390\/ijms222010977","article-title":"Chronic exposure to HIV-derived protein tat impairs endothelial function via indirect alteration in fat mass and Nox1-mediated mechanisms in mice[J]","volume":"22","author":"KOVACS","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2025.107812_bib40","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1096\/fj.13-246876","article-title":"HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis[J]","volume":"28","author":"CUI","year":"2014","journal-title":"Faseb J."},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib41","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s10439-012-0702-5","article-title":"Endothelial dysfunction, arterial stiffening, and intima-media thickening in large arteries from HIV-1 transgenic mice[J]","volume":"41","author":"HANSEN","year":"2013","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.phrs.2025.107812_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaf192","article-title":"Increased atherosclerosis in HIV-infected humanized mice is caused by a single viral protein, Nef[J]","author":"WANG","year":"2025","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.phrs.2025.107812_bib43","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1097\/QAD.0000000000002255","article-title":"Elevated indoleamine-2,3-dioxygenase enzyme activity in a novel mouse model of HIV-associated atherosclerosis[J]","volume":"33","author":"KEARNS","year":"2019","journal-title":"Aids"},{"issue":"9","key":"10.1016\/j.phrs.2025.107812_bib44","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1161\/ATVBAHA.119.312603","article-title":"Caspase-1 activation is related with HIV-associated atherosclerosis in an HIV transgenic mouse model and HIV patient cohort[J]","volume":"39","author":"KEARNS","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107812_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jmbi.1998.2354","article-title":"Structural biology of HIV[J]","volume":"285","author":"Turner","year":"1999","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107812_bib46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/ijms22010317","article-title":"HIV-1 tat protein enters dysfunctional endothelial cells via integrins and renders them permissive to virus replication[J]","volume":"22","author":"CAFARO","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2025.107812_bib47","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/febs.14657","article-title":"Vascular endothelial dysfunction in the wake of HIV and ART[J]","volume":"286","author":"MARINCOWITZ","year":"2019","journal-title":"Febs J."},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10557-021-07141-x","article-title":"HIV protein tat induces macrophage dysfunction and atherosclerosis development in low-density lipoprotein receptor-deficient mice[J]","volume":"36","author":"MENG","year":"2022","journal-title":"Cardiovasc Drugs Ther."},{"issue":"11-12","key":"10.1016\/j.phrs.2025.107812_bib49","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.cr.7290370","article-title":"Roles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactions[J]","volume":"15","author":"LI","year":"2005","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.phrs.2025.107812_bib50","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41594-020-0463-z","article-title":"Structural basis of CD4 downregulation by HIV-1 Nef[J]","volume":"27","author":"KWON","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107812_bib51","article-title":"Transfer of intracellular HIV Nef to endothelium causes endothelial dysfunction[J]","volume":"9","author":"WANG","year":"2014","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.phrs.2025.107812_bib52","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1161\/CIRCULATIONAHA.124.070538","article-title":"CD4(+) T cells expressing viral proteins induce HIV-associated endothelial dysfunction and hypertension through interleukin 1\u03b1-mediated increases in endothelial NADPH oxidase 1[J]","volume":"151","author":"KRESS","year":"2025","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib53","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1084\/jem.176.4.1099","article-title":"Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis[J]","volume":"176","author":"BANDA","year":"1992","journal-title":"J. Exp. Med"},{"issue":"25","key":"10.1016\/j.phrs.2025.107812_bib54","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/j.jacc.2017.05.012","article-title":"HIV-1-associated atherosclerosis: unraveling the missing link[J]","volume":"69","author":"KEARNS","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2025.107812_bib55","article-title":"Activated NK cells with pro-inflammatory features are associated with atherogenesis in perinatally HIV-acquired adolescents[J]","author":"Alles","year":"2023","journal-title":"medRxiv"},{"issue":"11","key":"10.1016\/j.phrs.2025.107812_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0040365","article-title":"Human immunodeficiency virus impairs reverse cholesterol transport from macrophages[J]","volume":"4","author":"MUJAWAR","year":"2006","journal-title":"PLoS Biol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib57","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3390\/ijms25042367","article-title":"HIV infection drives foam cell formation via NLRP3 inflammasome activation[J]","volume":"25","author":"CAOCCI","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107812_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.821568","article-title":"Arterial stiffness in a cohort of young people living with perinatal HIV and HIV negative young people in England[J]","volume":"9","author":"MELLIN","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib59","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.atherosclerosis.2006.12.022","article-title":"Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis[J]","volume":"196","author":"LORENZ","year":"2008","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.phrs.2025.107812_bib60","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/QAD.0000000000002615","article-title":"Monocyte activation and gut barrier dysfunction in South African youth on antiretroviral therapy and their associations with endothelial dysfunction[J]","volume":"34","author":"DIRAJLAL-FARGO","year":"2020","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.phrs.2025.107812_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/19932820.2023.2215636","article-title":"Association between cardio-ankle vascular index and cardiometabolic risk factors in HIV patients in Ghana[J]","volume":"18","author":"YEBOAH","year":"2023","journal-title":"Libyan J. Med"},{"issue":"13","key":"10.1016\/j.phrs.2025.107812_bib62","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jbiomech.2016.05.018","article-title":"Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia[J]","volume":"49","author":"GLEASON","year":"2016","journal-title":"J. Biomech."},{"issue":"11","key":"10.1016\/j.phrs.2025.107812_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0310056","article-title":"Soluble P-selectin as an inflammatory mediator potentially influencing endothelial activation in people living with HIV in sub-rural areas of Limpopo, South Africa[J]","volume":"19","author":"MOKOENA","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2025.107812_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.980754","article-title":"Increased endothelial biomarkers are associated with HIV antiretroviral therapy and C-reactive protein among a African rural population in Limpopo Province, South Africa[J]","volume":"10","author":"HANSER","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.phrs.2025.107812_bib65","article-title":"Serum uric acid and high-sensitivity C-reactive protein levels among people living with HIV on dolutegravir and ritonavir-boosted atazanavir-based antiretroviral therapy: a comparative cross-sectional study[J]","volume":"11","author":"WARITU","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"9622","key":"10.1016\/j.phrs.2025.107812_bib66","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration[J]","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib67","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/QAI.0b013e31826f993c","article-title":"No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis[J]","volume":"61","author":"DING","year":"2012","journal-title":"J. Acquir Immune Defic. Syndr."},{"issue":"16","key":"10.1016\/j.phrs.2025.107812_bib68","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/QAD.0b013e328349c6ee","article-title":"Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data[J]","volume":"25","author":"CRUCIANI","year":"2011","journal-title":"Aids"},{"key":"10.1016\/j.phrs.2025.107812_bib69","article-title":"The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI\/NNRTI and NRTI\/INSTI[J]","volume":"11","author":"LIU","year":"2023","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.phrs.2025.107812_bib70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12944-023-01786-3","article-title":"Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study[J]","volume":"22","author":"YU","year":"2023","journal-title":"Lipids Health Dis."},{"issue":"7","key":"10.1016\/j.phrs.2025.107812_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12878","article-title":"Retinal vessel functional responses in South Africans living with and without HIV: the endoAfrica-NWU study[J]","volume":"31","author":"MYBURGH-JACOBSZ","year":"2024","journal-title":"Microcirculation"},{"issue":"3","key":"10.1016\/j.phrs.2025.107812_bib72","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/v14030578","article-title":"VCAM-1 as a biomarker of endothelial function among hiv-infected patients receiving and not receiving antiretroviral therapy[J]","volume":"14","author":"LEMBAS","year":"2022","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.phrs.2025.107812_bib73","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(22)00094-7","article-title":"Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium[J]","volume":"9","author":"NEESGAARD","year":"2022","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib74","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/01.qai.0000228790.40235.0c","article-title":"Antiretrovirals induce direct endothelial dysfunction in vivo[J]","volume":"42","author":"JIANG","year":"2006","journal-title":"J. Acquir Immune Defic. Syndr."},{"issue":"6","key":"10.1016\/j.phrs.2025.107812_bib75","doi-asserted-by":"crossref","first-page":"H2363","DOI":"10.1152\/ajpheart.00151.2002","article-title":"Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide[J]","volume":"283","author":"SUTLIFF","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"21","key":"10.1016\/j.phrs.2025.107812_bib76","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1161\/CIRCULATIONAHA.113.001278","article-title":"Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice[J]","volume":"127","author":"CIPRIANI","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2025.107812_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226924","article-title":"HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells[J]","volume":"15","author":"AUCLAIR","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib78","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12012-016-9397-4","article-title":"Effect of the anti-retroviral drugs efavirenz, tenofovir and emtricitabine on endothelial cell function: role of PARP[J]","volume":"17","author":"FALTZ","year":"2017","journal-title":"Cardiovasc Toxicol."},{"key":"10.1016\/j.phrs.2025.107812_bib79","article-title":"Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function[J]","volume":"14","author":"HUANG","year":"2023","journal-title":"Front Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib80","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1124\/mol.115.098590","article-title":"Dysregulation of endoplasmic reticulum stress and autophagic responses by the antiretroviral drug efavirenz[J]","volume":"88","author":"BERTRAND","year":"2015","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib81","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202402677RR","article-title":"Dolutegravir induces endoplasmic reticulum stress at the blood-brain barrier[J]","volume":"39","author":"HUANG","year":"2025","journal-title":"Faseb J."},{"issue":"ement_1","key":"10.1016\/j.phrs.2025.107812_bib82","article-title":"The effects of HIV-1-proteins and antiretroviral therapy on aortic endothelial cells (AECs). A mechanistic in vitro approach[J]","volume":"120","author":"GENIS","year":"2024","journal-title":"Cardiovasc. Res."},{"issue":"12","key":"10.1016\/j.phrs.2025.107812_bib83","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1161\/ATVBAHA.110.213603","article-title":"Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin[J]","volume":"30","author":"Lef\u00e8vre","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107812_bib84","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.taap.2007.06.010","article-title":"HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis[J]","volume":"224","author":"JIANG","year":"2007","journal-title":"Toxicol. Appl. Pharm."},{"issue":"9","key":"10.1016\/j.phrs.2025.107812_bib85","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1161\/CIRCULATIONAHA.118.036232","article-title":"Senescent phenotype induced by p90RSK-NRF2 signaling sensitizes monocytes and macrophages to oxidative stress in hiv-positive individuals[J]","volume":"139","author":"SINGH","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.phrs.2025.107812_bib86","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/labinvest.2009.85","article-title":"Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells[J]","volume":"89","author":"WANG","year":"2009","journal-title":"Lab Invest"},{"key":"10.1016\/j.phrs.2025.107812_bib87","series-title":"StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Vini Vijayan declares no relevant financial relationships with ineligible companies","article-title":"HIV-Associated Lipodystrophy [M]","author":"Guzman","year":"2025"},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib88","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.qai.0000232610.93867.2f","article-title":"Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury[J]","volume":"43","author":"KAPPERT","year":"2006","journal-title":"J. Acquir Immune Defic. Syndr."},{"issue":"5","key":"10.1016\/j.phrs.2025.107812_bib89","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jacc.2018.04.083","article-title":"Protease inhibitors and cardiovascular outcomes in patients with HIV and heart failure[J]","volume":"72","author":"ALVI","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107812_bib90","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cardiores.2004.03.020","article-title":"HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries[J]","volume":"63","author":"CONKLIN","year":"2004","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.phrs.2025.107812_bib91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12012-007-9010-y","article-title":"Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects[J]","volume":"8","author":"DUB\u00c9","year":"2008","journal-title":"Cardiovasc Toxicol."},{"issue":"7","key":"10.1016\/j.phrs.2025.107812_bib92","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1086\/378064","article-title":"Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review[J]","volume":"37","author":"RHEW","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.phrs.2025.107812_bib93","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors[J]","volume":"12","author":"CARR","year":"1998","journal-title":"Aids"},{"issue":"9170","key":"10.1016\/j.phrs.2025.107812_bib94","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study[J]","volume":"353","author":"CARR","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107812_bib95","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.atherosclerosis.2017.05.004","article-title":"Cardiovascular risk in advanced na\u00efve HIV-infected patients starting antiretroviral therapy: comparison of three different regimens - PREVALEAT II cohort[J]","volume":"263","author":"MAGGI","year":"2017","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.phrs.2025.107812_bib96","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/jac\/dkq507","article-title":"Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens[J]","volume":"66","author":"MAGGI","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.phrs.2025.107812_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045716","article-title":"Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study[J]","volume":"7","author":"GUPTA","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2025.107812_bib98","first-page":"63","article-title":"[Interventional study on Dolutegravir and other antiretrovirals in patients with subclinical atherosclerosis in the Kinshasa Hospital][J]","volume":"45","author":"MASHI","year":"2023","journal-title":"Pan Afr. Med J."},{"issue":"8","key":"10.1016\/j.phrs.2025.107812_bib99","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3851\/IMP3160","article-title":"Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence[J]","volume":"22","author":"AFONSO","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.phrs.2025.107812_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/srep28853","article-title":"Maraviroc reduces arterial stiffness in PI-treated HIV-infected patients[J]","volume":"6","author":"PICONI","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.phrs.2025.107812_bib101","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cvr\/cvt333","article-title":"The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro[J]","volume":"101","author":"MAGUIRE","year":"2014","journal-title":"Cardiovasc Res"},{"issue":"23","key":"10.1016\/j.phrs.2025.107812_bib102","first-page":"12389","article-title":"Integrase inhibitor-based antiretroviral treatments decrease oxidative stress caused by HIV infection[J]","volume":"24","author":"Akkoyunlu","year":"2020","journal-title":"Eur. Rev. Med Pharm. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2025.107812_bib103","doi-asserted-by":"crossref","first-page":"C487","DOI":"10.1152\/ajpcell.00600.2023","article-title":"Cenicriviroc prevents dysregulation of astrocyte\/endothelial cross talk induced by ischemia and HIV-1 via inhibiting the NLRP3 inflammasome and pyroptosis[J]","volume":"326","author":"FATTAKHOV","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"22","key":"10.1016\/j.phrs.2025.107812_bib104","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.jacc.2018.09.038","article-title":"IL-1\u03b2 inhibition reduces atherosclerotic inflammation in HIV infection[J]","volume":"72","author":"HSUE","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.phrs.2025.107812_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049330","article-title":"Effect of aspirin on HIV disease progression among HIV-infected individuals initiating antiretroviral therapy: study protocol for a randomised controlled trial[J]","volume":"11","author":"MWAKYANDILE","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.phrs.2025.107812_bib106","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ahj.2018.12.016","article-title":"Rationale and design of the randomized trial to prevent vascular events in HIV (REPRIEVE)[J]","volume":"212","author":"GRINSPOON","year":"2019","journal-title":"Am. Heart J."},{"issue":"20","key":"10.1016\/j.phrs.2025.107812_bib107","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jacc.2020.03.025","article-title":"Evolocumab in HIV-infected patients with dyslipidemia: primary results of the randomized, double-blind BEIJERINCK study[J]","volume":"75","author":"BOCCARA","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107812_bib108","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/hiv.13533","article-title":"Influence of physical activity on endothelial function in people living with HIV[J]","volume":"25","author":"PREVEDEN","year":"2024","journal-title":"HIV Med"},{"issue":"5","key":"10.1016\/j.phrs.2025.107812_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26051837","article-title":"Cardiovascular disease in HIV patients: a comprehensive review of current knowledge and clinical implications[J]","volume":"26","author":"\u0218OLDEA","year":"2025","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107812_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.982746","article-title":"The 2000HIV study: design, multi-omics methods and participant characteristics[J]","volume":"13","author":"VOS","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2025.107812_bib111","article-title":"Novel molecules targeting metabolism and mitochondrial function in cardiac diseases[J]","author":"GONZALEZ","year":"2025","journal-title":"Curr. Cardiol. Rev."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825002373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825002373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T23:09:47Z","timestamp":1764976187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825002373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":111,"alternative-id":["S1043661825002373"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107812","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV infection, antiretroviral therapy and vascular dysfunction: Effects, mechanisms and treatments","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107812"}}